We are live on ! Find out more
SCPS

Scopus BioPharma Inc. Common Stock
SCPS

Delisted

SCPS was delisted on the 16th of December, 2022.

Back to rankings

0 hedge funds and large institutions have $0 invested in Scopus BioPharma Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $7.49K → $0 (-$7.49K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
–
Holders Change
-1
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
MRCM
M&R Capital Management
New Jersey
-$7.49K
Name Holding Trade Value Shares
Change 		Change in
Stake
MRCM
1
M&R Capital Management
New Jersey
– -$7.49K -76,819 Closed

SCPS Hedge Fund Activity: Q1 2023 in Review

0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Scopus BioPharma Inc. Common Stock (SCPS) for Q1 2023, worth a combined $0 — down 100% from $7.49K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of SCPS and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was M&R Capital Management, exiting entirely with an estimated $7.49K sold.

  • 0 institutional investors held Scopus BioPharma Inc. Common Stock (SCPS) as of Q1 2023, down from 1 in Q4 2022.
  • Funds reported $0 of Scopus BioPharma Inc. Common Stock stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Scopus BioPharma Inc. Common Stock positions in Q1 2023 and 1 closed out, a net change of -1 holder.
  • The largest Scopus BioPharma Inc. Common Stock seller in Q1 2023 was M&R Capital Management, an estimated $7.49K sold.

Based on aggregated 13F filings for Q1 2023.